Higher-Risk Chronic Myelomonocytic Leukemia Market Analysis, Pipeline, Epidemiology, Treatment, Drugs, Companies by DelveInsight | Sensei Biotherapeutic, Argenx, Novartis, Kura Oncology, Takeda,Others

Higher-Risk Chronic Myelomonocytic Leukemia Market

DelveInsight’s “Higher-Risk Chronic Myelomonocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Higher-Risk Chronic Myelomonocytic Leukemia , historical and forecasted epidemiology as well as the Higher-Risk Chronic Myelomonocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Higher Risk Chronic Myelomonocytic Leukemia Market are:

CMML affects approximately 3 out of 100,000 individuals in the United States each year.
The risk of CMML increases with age. This disease is rare in those younger than 40, with most cases found in people 60 and older.
Median survival of patients with CMML is reported to be approximately 12 to 40 months.
Through various secondary studies it can be concluded that overall HR-CMML affects more males than females.
The disease incidence rate ranges between 3.5 and 4.1/1 000 000 per year in the United States and in Europe.
On an average, patients with CMML demonstrate ~10-15 mutations per kilobase of coding DNA regions, similar to patients with acute myeloid leukemia (AML), but several folds lower than other malignancies such as melanoma and lung cancer.

 

Request for Free Sample Reporthttps://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Some of Higher Risk Chronic Myelomonocytic Leukemia companies are:

Pharmion Corporation
Otsuka America Pharmaceutical
Argenx
Novartis
Kura Oncology
Sensei Biotherapeutics
Takeda
Humanigen
And Many Others

 

Chronic Myelomonocytic Leukemia (CMML) is a rare, clonal hematopoietic stem cell disorder characterized by the presence of sustained (>3 months) peripheral blood (PB) monocytosis (≥1 × 109/L; monocytes ≥10% of white blood cell count) along with dysplastic features in the bone marrow (BM). CMML has some similarities with a condition called myelodysplastic syndrome (MDS) and some resemblance to a group of conditions called myeloproliferative neoplasms (MPN). It is classified as being a mixture of these two conditions.

CMML shares clinical and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities.

CMML can be further subdivided into two categories depending on the number of blasts found in the peripheral blood and bone marrow, CMML-1 with less than 5% blasts in peripheral blood and less than 10% in bone marrow, and CMML-2 with 5 to 19% blasts in peripheral blood and/or 10 and 19% in the bone marrow.

 

Some of Higher Risk Chronic Myelomonocytic Leukemia therapies are:

Vidaza
Dacogen
Cusatuzumab
MBG453
Tipifarnib
SNS-301
Pevonedistat
Lenzilumab
And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/higher-risk-chronic-myelomonocytic-leukemia-market

 

Table of Contents:

Key Insights
Executive Summary of Higher-Risk Chronic Myelomonocytic Leukemia
Competitive Intelligence Analysis for Higher-Risk Chronic Myelomonocytic Leukemia
Higher-Risk Chronic Myelomonocytic Leukemia : Market Overview at a Glance
Higher-Risk Chronic Myelomonocytic Leukemia : Disease Background and Overview
Patient Journey
Higher-Risk Chronic Myelomonocytic Leukemia Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Higher-Risk Chronic Myelomonocytic Leukemia Treatment
Marketed Products

List to be continued in report

Emerging Therapies

List to be continued in report

Higher-Risk Chronic Myelomonocytic Leukemia : Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Higher-Risk Chronic Myelomonocytic Leukemia
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/higher-risk-chronic-myelomonocytic-leukemia-market